Anebulo Pharmaceuticals (Anebulo Pharmaceuticals) Net-Net Working Capital : $0.16 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Anebulo Pharmaceuticals Net-Net Working Capital?

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.

Anebulo Pharmaceuticals's Net-Net Working Capital for the quarter that ended in Mar. 2024 was $0.16.

The industry rank for Anebulo Pharmaceuticals's Net-Net Working Capital or its related term are showing as below:

ANEB's Price-to-Net-Net-Working-Capital is ranked worse than
80.52% of 924 companies
in the Biotechnology industry
Industry Median: 4.275 vs ANEB: 13.13

Anebulo Pharmaceuticals Net-Net Working Capital Historical Data

The historical data trend for Anebulo Pharmaceuticals's Net-Net Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anebulo Pharmaceuticals Net-Net Working Capital Chart

Anebulo Pharmaceuticals Annual Data

Trend

Jun20

Jun21

Jun22

Jun23

Net-Net Working Capital

0.85

0.60

0.40

Anebulo Pharmaceuticals Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net-Net Working Capital	Get a 7-Day Free Trial										0.49	0.40	0.30	0.22	0.16

Competitive Comparison of Anebulo Pharmaceuticals's Net-Net Working Capital

For the Biotechnology subindustry, Anebulo Pharmaceuticals's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Anebulo Pharmaceuticals's Price-to-Net-Net-Working-Capital Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anebulo Pharmaceuticals's Price-to-Net-Net-Working-Capital distribution charts can be found below:

* The bar in red indicates where Anebulo Pharmaceuticals's Price-to-Net-Net-Working-Capital falls into.

Anebulo Pharmaceuticals Net-Net Working Capital Calculation

Anebulo Pharmaceuticals's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Jun. 2023 is calculated as

	Net-Net Working Capital		(A: Jun. 2023 )
=	(Cash, Cash Equivalents, Marketable Securities	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(11.247	+	0.75 * 0	+	0.5 * 0	-	1.069
-	0	-	0)	/	25.6332
=	0.40

Anebulo Pharmaceuticals's Net-Net Working Capital (NNWC) per share for the quarter that ended in Mar. 2024 is calculated as

	Net-Net Working Capital		(Q: Mar. 2024 )
=	(Cash, Cash Equivalents, Marketable Securities	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(5.147	+	0.75 * 0	+	0.5 * 0	-	1.01
-	0	-	0)	/	25.9332
=	0.16

In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

This is a conservative way of estimating the company's value.

Anebulo Pharmaceuticals (NAS:ANEB) Net-Net Working Capital Explanation

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.

Anebulo Pharmaceuticals Net-Net Working Capital Related Terms

Thank you for viewing the detailed overview of Anebulo Pharmaceuticals's Net-Net Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Anebulo Pharmaceuticals (Anebulo Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anebulo Pharmaceuticals Inc (NAS:ANEB) » Definitions » Net-Net Working Capital

Comparable Companies

Traded in Other Exchanges

214:Germany

Address

1017 Ranch Road 620 South, Suite 107, Lakeway, TX, USA, 78734

Website

https://www.anebulo.com

Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company. It is developing novel solutions for people suffering from cannabinoid overdose and substance addiction. The product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within 1 hour of administration. The signs and symptoms of cannabinoid overdose range from profound sedation to anxiety and panic to psychosis with hallucinations.

Executives

Bimal R. Shah	director	C/O SPECTRUM PHARMACEUTICALS, 11500 SOUTH EASTER AVENUE, SUITE 240, HENDERSON NV 89052
Richard Anthony Cunningham,	director, officer: Chief Executive Officer	ONE KENDALL SQUARE, BUILDING 200 SUITE 2, CAMBRIDGE MA 02139
Dan George	officer: Chief Financial Officer	1412 62ND STREET, EMERYVILLE CA 94608
Sandra A. Gardiner	officer: Acting Chief Financial Officer	CUTERA, INC., 3240 BAYSHORE BOULEVARD, BRISBANE CA 94005
Kenneth C Cundy	officer: Chief Scientific Officer	1455 ADAMS DRIVE, SUITE 2050, MENLO BUSINESS PARK, MENLO PARK CA 94025
Nathaniel Calloway	director	C/O ANEBULO PHARMACEUTICALS, INC., 1415 RANCH ROAD 620 SOUTH, SUITE 201, LAKEWAY TX 78734
Simon Allen	director, officer: Chief Executive Officer	C/O AMBRX, INC., 10975 N. TORREY PINES RD., LA JOLLA CA 92037
Aron R. English	director, 10 percent owner	1455 NW LEARY WAY, SUITE 400, SEATTLE WA 98107
Kenneth Lin	director	PO BOX 1005, LOS ALTOS CA 94022
Karah Herdman Parschauer	director	60 LEVERONI COURT, NOVATO CA 94949
22nw Fund, Lp	10 percent owner	1455 NW LEARY WAY, SUITE 400, SEATTLE WA 98107
Joseph F. Lawler	director, 10 percent owner	2110 RANCH ROAD 620 S, #341732, LAKEWAY TX 78734
Areta Kupchyk	director	C/O ANEBULO PHARMACEUTICALS, INC., 1415 RANCH ROAD 620 SOUTH, SUITE 201, LAKEWAY TX 78734
Jason Aryeh	director	11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
22nw, Lp	10 percent owner, other: See Explanation of Response	590 1ST AVE S, UNIT C1, SEATTLE WA 98104